Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL488856 | 0.87 | SLC6A2 (0.40) | TAAR1P2RX7IDO1SMN1; SMN2 | |
| SCHEMBL29395789 | 0.87 | SLC6A2 (0.40) | TAAR1P2RX7IDO1SMN1; SMN2 | |
| SCHEMBL11537654 | 0.87 | IDO1 (0.41) | TAAR1P2RX7IDO1ALDH1A1POLB | |
| SCHEMBL11520584 | 0.87 | TAAR1 (0.39) | TAAR1P2RX7IDO1ALDH1A1POLB | |
| SCHEMBL25372761 | 0.85 | TAAR1 (0.38) | TAAR1P2RX7IDO1ALDH1A1TDP1 | |
| SCHEMBL29393476 | 0.85 | P2RX7 (0.41) | TAAR1P2RX7L3MBTL1SMN1; SMN2 | |
| SCHEMBL696040 | 0.85 | P2RX7 (0.41) | TAAR1P2RX7L3MBTL1SMN1; SMN2 | |
| SCHEMBL30723660 | 0.82 | GABRA1 (0.42) | TAAR1P2RX7IDO1POLBSMN1; SMN2 | |
| SCHEMBL2885303 | 0.81 | HSD11B1 (0.42) | ALDH1A1CES1HSD17B10 | |
| SCHEMBL25371546 | 0.80 | MAPT (0.41) | POLBTDP1L3MBTL1HTR2CSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10201545-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-9421210-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160193160-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. | 2016-07-07 | — | — | US | disclosed |
| US-9314467-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150238497-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150166495-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150166494-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. | 2015-06-18 | — | — | US | disclosed |
| US-8653142-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130253064-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2013-09-26 | — | — | US | disclosed |
| US-8420863-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| EP-2076124-A2 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20090170841-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. (US) | 2009-07-02 | — | — | US | disclosed |
| EP-1718605-B1 | PROCESSES FOR THE PREPARATION OF ARYL-AND HETEROARYL-ALKYLSULFONYL HALIDES | WYETH CORP (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008131368-A2 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166495-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ALDH1A2, STARD3, TXNRD2 | TAAR1 2715/4885P2RX7 3067/4885IDO1 3146/4885 |
| US-20150166494-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ALDH1A2, STARD3, TXNRD2 | TAAR1 2715/4885P2RX7 3067/4885IDO1 3146/4885 |
| US-20130253064-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, STARD3, TXNRD2 | TAAR1 2715/4885P2RX7 3067/4885IDO1 3146/4885 |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | TAAR1 117/4885P2RX7 935/4885IDO1 54/4885 |
| US-20150238497-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, STARD3, TXNRD2 | TAAR1 2715/4885P2RX7 3067/4885IDO1 3146/4885 |
| US-20160193160-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ALDH1A2, STARD3, TXNRD2 | TAAR1 2715/4885P2RX7 3067/4885IDO1 3146/4885 |
| US-10201545-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ALDH1A2, STARD3, TXNRD2 | TAAR1 2715/4885P2RX7 3067/4885IDO1 3146/4885 |
| US-20090170841-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ALDH1A2, STARD3, TXNRD2 | TAAR1 2715/4885P2RX7 3067/4885IDO1 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.